Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed-Reference-Cited by-同舟云学术

Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

Published:2022-08-24 Issue:10 Volume:39 Page:4821-4835
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Citrome Leslie^ORCID,Risinger Robert,Rajachandran Lavanya,Robison Heather

Funder

BioXcel Therapeutics

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02274-3.pdf

Reference28 articles.

1. Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17(2):86–128.

2. Sacchetti E, Valsecchi P, Tamussi E, Paulli L, Morigi R, Vita A. Psychomotor agitation in subjects hospitalized for an acute exacerbation of Schizophrenia. Psychiatry Res. 2018;270:357–64.

3. Alderfer BS, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry. 2003;64(Suppl 4):3–9.

4. Martinez-Raga J, Amore M, Di Sciascio G, et al. 1st International experts’ meeting on agitation: conclusions regarding the current and ideal management paradigm of agitation. Front Psychiatry. 2018;9:54.

5. Pacciardi B, Calcedo A, Messer T. Inhaled loxapine for the management of acute agitation in bipolar disorder and schizophrenia: expert review and commentary in an era of change. Drugs R D. 2019;19(1):15–25.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study;The American Journal on Addictions;2024-08-16

2. DEXMEDETOMIDINE;Prescriber's Guide;2024-04-18

3. An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders;CNS Drugs;2024-03-19

4. Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder;Expert Opinion on Pharmacotherapy;2023-09-04

5. Sublingual Dexmedetomidine for the Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder;Clinical Psychopharmacology and Neuroscience;2023-05-30